Vaccine Production Program Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Gaithersburg, Maryland 20878, United States.
J Am Soc Mass Spectrom. 2021 Jul 7;32(7):1837-1840. doi: 10.1021/jasms.1c00075. Epub 2021 Jun 24.
For conjugated HIV-1 fusion peptide vaccine development, recombinant Tetanus toxoid heavy chain fragment C (rTTHC) was applied as a carrier protein to boost peptide immunogenicity. Understanding the characteristics of rTTHC is the first step prior to the peptide conjugation. A comprehensive mass spectrometry (MS) characterization was performed on expressed rTTHC during its purification process. Intact mass along with peptide mapping analysis discovered the existence of three cysteine modification forms: glutathionylation, trisulfide bond modification, and disulfide bond shuffling, in correlation to a three-peak profile during a hydrophobic interaction chromatography (HIC) purification step. Coexistence of these multiple oxidative forms indicated that the active thiols underwent redox reaction in the rTTHC material. Identity confirmation of the rTTHC carrier protein by MS analysis provided pivotal guidance to assess the purification step and helped ensure that vaccine development could proceed.
为了开发与 HIV-1 融合肽偶联的疫苗,我们应用破伤风类毒素重链片段 C(rTTHC)作为载体蛋白来增强肽的免疫原性。在进行肽偶联之前,了解 rTTHC 的特性是首要步骤。在 rTTHC 的纯化过程中,我们对表达产物进行了全面的质谱(MS)分析。完整质量分析和肽图分析发现,rTTHC 存在三种半胱氨酸修饰形式:谷胱甘肽化、三硫键修饰和二硫键重排,与疏水相互作用色谱(HIC)纯化步骤中的三峰图谱相关。这些多种氧化形式的共存表明,rTTHC 材料中的活性巯基发生了氧化还原反应。通过 MS 分析对 rTTHC 载体蛋白进行身份确认,为评估纯化步骤提供了关键指导,并有助于确保疫苗的开发能够顺利进行。